Capital World Investors
GEVA

Capital World Investors’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Capital World Investors’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,262,798
Closed -$123M – 558
2015
Q1 		$123M Buy
1,262,798
+230,100
+22% +$24.4M 0.03% 284
2014
Q4 		$95.8M Buy
1,032,698
+89,000
+9% +$7.02M 0.03% 302
2014
Q3 		$64.9M Hold
943,698
– – 0.02% 344
2014
Q2 		$98.9M Sell
943,698
-84,700
-8% -$7.21M 0.03% 311
2014
Q1 		$85.3M Buy
1,028,398
+483,698
+89% +$44.7M 0.02% 308
2013
Q4 		$35.3M Buy
544,700
+14,700
+3% +$872K 0.01% 369
2013
Q3 		$33.6M Buy
530,000
+305,000
+136% +$15M 0.01% 374
2013
Q2 		$9.45M Buy
+225,000
New +$10.3M ﹤0.01% 438

Capital World Investors's GEVA Position: Q2 2015 in Review

Capital World Investors sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 1,262,798 shares — an estimated $123M sold.

Capital World Investors first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $123M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Capital World Investors reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Capital World Investors sold 1,262,798 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $123M.
  • Capital World Investors first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Capital World Investors's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $123M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Capital World Investors's 13F filing for Q2 2015, filed 14 Aug 2015.